#HVO hVIVO PLC – Acquisition of Cryostore for up to £3.2m February 27, 2025 – Posted in: Blog, hVIVO (HVO), Uncategorized

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it has acquired Cryo-Store Limited (“Cryostore” or the “Acquisition”), a specialist provider of high industry standard, temperature-controlled storage solutions for biological and clinical materials. The Acquisition has been completed for consideration of up to £3.2 million, comprising £2.7 million funded from the Group’s existing cash resources and up to £0.5 million in equity…

#HVO hVIVO PLC – £3.2m hLAB project January 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m. As part of this new contract, hLAB will act as the only contracted virology…

#TSP TruSpine Technologies – Further re: FDA Update October 30, 2023 – Posted in: Blog, TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems announces that, further to the announcement on 12 October 2023, the Company has received communication from the U.S. Food and Drug Administration (“FDA”) that its FDA 510(k) application has been progressed to the substantive review stage. CEO Laurence Strauss commented: “I am delighted that after the prompt response of the Company in providing clarification and…

Poolbeg Pharma #POLB – AI programme yields novel RSV drug targets March 29, 2022 – Posted in: Poolbeg Pharma (POLB)

AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech , Inc. through…

Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets March 28, 2022 – Posted in: Poolbeg Pharma (POLB)

Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with…

Tiziana Life Sciences (TILS) Interim Results for the Six Months Ended 30 June 2019 September 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2019. Highlights during the period: RESEARCH & DEVELOPMENT CLINICAL PROGRAMMES Foralumab TZLS-401 Foralumab…

Tiziana Life Sciences #TILS Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers September 16, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers. A breakthrough approach for treatment of autoimmune and inflammatory diseases London, 16…

The Appliance of Life Science Looks Exciting for this On-the-Nose Medical Explorer. September 11, 2019 – Posted in: Tiziana Life Sciences (TILS)

by Malcolm Stacey Hello, Share Troopers. Previously, I’ve written on the huge potential of life science companies which explore antibodies and antibody substitutes in the fight against serious conditions like cancer. Allow me to put another such firm before you. Tiziana Life Sciences plc (TILS) is biotechnology outfit which uses antibodies to find new treatments for inflammatory diseases and cancers. The company has just announced good news which sent the share price alight this week.…

Tiziana Life Sciences #TILS Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers September 10, 2019 – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences plc Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers New…

Tiziana Life Sci PLC (TILS) Teplizumab Article July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana’s Foralumab, the only known fully human anti-CD3 mAb Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population Tiziana Life…